| Edgardo E Li-espino, MD | |
|
5147 N 9th Ave, Suite 322, Pensacola, FL 32504-8771 | |
| (850) 439-5681 | |
| (850) 439-5682 |
| Full Name | Edgardo E Li-espino |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 34 Years |
| Location | 5147 N 9th Ave, Pensacola, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285768432 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | ME83674 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sacred Heart Hospital | Pensacola, FL | Hospital |
| West Florida Hospital | Pensacola, FL | Hospital |
| Baptist Hospital | Pensacola, FL | Hospital |
| South Baldwin Regional Medical Center | Foley, AL | Hospital |
| D W Mcmillan Memorial Hospital | Brewton, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Center For Prevention And Treatment Of Infections, P.a. | 0244461168 | 3 |
News Archive
Nearly 1 in 10 children have asthma, according to government statistics, and in low-income parts of Boston, nearly 16 percent of children are affected. A program called the Community Asthma Initiative (CAI), developed and implemented in 2005 by clinicians at Children's Hospital Boston, demonstrates the potential to dramatically reduce hospitalization and emergency department visits for asthma - improving patient outcomes and saving $1.46 per dollar spent through reduced hospital utilization.
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
Today, the U.S. Food and Drug Administration issued final guidance for developers of mobile medical applications, or apps, which are software programs that run on mobile communication devices and perform the same functions as traditional medical devices. The guidance outlines the FDA's tailored approach to mobile apps.
A minimally invasive endoscopic procedure holds promise for safely removing large brain tumors from an area at the bottom of the skull, near the sinus cavities, clinical researchers at the Brain Tumor Center at the University of Cincinnati Neuroscience Institute (UCNI) at University Hospital have found.
Shedding light on a decades-old controversy, scientists at the Medical University of South Carolina and University of California at San Diego published findings in PLOS Genetics this month showing that autophagy or "self-eating" genes work against tumors in certain types of ovarian cancer.
› Verified 5 days ago
| Entity Name | Center For Prevention And Treatment Of Infections, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811311004 PECOS PAC ID: 0244461168 Enrollment ID: O20140318001081 |
News Archive
Nearly 1 in 10 children have asthma, according to government statistics, and in low-income parts of Boston, nearly 16 percent of children are affected. A program called the Community Asthma Initiative (CAI), developed and implemented in 2005 by clinicians at Children's Hospital Boston, demonstrates the potential to dramatically reduce hospitalization and emergency department visits for asthma - improving patient outcomes and saving $1.46 per dollar spent through reduced hospital utilization.
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
Today, the U.S. Food and Drug Administration issued final guidance for developers of mobile medical applications, or apps, which are software programs that run on mobile communication devices and perform the same functions as traditional medical devices. The guidance outlines the FDA's tailored approach to mobile apps.
A minimally invasive endoscopic procedure holds promise for safely removing large brain tumors from an area at the bottom of the skull, near the sinus cavities, clinical researchers at the Brain Tumor Center at the University of Cincinnati Neuroscience Institute (UCNI) at University Hospital have found.
Shedding light on a decades-old controversy, scientists at the Medical University of South Carolina and University of California at San Diego published findings in PLOS Genetics this month showing that autophagy or "self-eating" genes work against tumors in certain types of ovarian cancer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Edgardo E Li-espino, MD 5147 N 9th Ave, Suite 322, Pensacola, FL 32504-8771 Ph: (850) 439-5681 | Edgardo E Li-espino, MD 5147 N 9th Ave, Suite 322, Pensacola, FL 32504-8771 Ph: (850) 439-5681 |
News Archive
Nearly 1 in 10 children have asthma, according to government statistics, and in low-income parts of Boston, nearly 16 percent of children are affected. A program called the Community Asthma Initiative (CAI), developed and implemented in 2005 by clinicians at Children's Hospital Boston, demonstrates the potential to dramatically reduce hospitalization and emergency department visits for asthma - improving patient outcomes and saving $1.46 per dollar spent through reduced hospital utilization.
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
Today, the U.S. Food and Drug Administration issued final guidance for developers of mobile medical applications, or apps, which are software programs that run on mobile communication devices and perform the same functions as traditional medical devices. The guidance outlines the FDA's tailored approach to mobile apps.
A minimally invasive endoscopic procedure holds promise for safely removing large brain tumors from an area at the bottom of the skull, near the sinus cavities, clinical researchers at the Brain Tumor Center at the University of Cincinnati Neuroscience Institute (UCNI) at University Hospital have found.
Shedding light on a decades-old controversy, scientists at the Medical University of South Carolina and University of California at San Diego published findings in PLOS Genetics this month showing that autophagy or "self-eating" genes work against tumors in certain types of ovarian cancer.
› Verified 5 days ago
Mohamed K Helmi, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5149 N. 9th Ave., Suite 120, Pensacola, FL 32504 Phone: 850-477-9253 Fax: 850-494-9843 | |
Dr. Peter A Marco, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5149 N. 9th Avenue, Suite 120, Pensacola, FL 32504 Phone: 850-477-9253 Fax: 850-494-9843 | |
Dr. Paul T Castro, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 8383 N Davis Hwy, West Florida Hospital, Pensacola, FL 32514 Phone: 850-494-5403 Fax: 850-494-4382 | |
Alejandro A Inclan, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4724 N Davis Hwy, Pensacola, FL 32503 Phone: 850-696-4000 Fax: 850-444-7057 | |
Dr. Samual Wade Sauer, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4451 Bayou Blvd, Pensacola, FL 32503 Phone: 850-416-7619 Fax: 850-416-7753 | |
Dr. Robert E Bondurant, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 10095 Hillview Dr, Pensacola, FL 32514 Phone: 850-479-4000 Fax: 850-479-4034 | |
Dr. Edgar Antonio Gonzalez, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 6000 W Highway 98, Pensacola Naval Hospital, Pensacola, FL 32512 Phone: 850-515-7171 |